The University of Texas M. D. Anderson Cancer Center (MDACC) is a free-standing comprehensive cancer center established within the University of Texas system. The mission of the MDACC is to eliminate cancer in Texas, the nation and the world through outstanding integrated programs of patient care, research, education and prevention. MDACC is dedicated wholly to the study of cancer involving a continuum of basic, clinical and population-based investigation, with an emphasis on multidisciplinary translational research. During the last 5 years, the number of cancer center members has increased 52%, facilities including those under construction have increased 32% and new patients have increased 32%. Publications listed in Pub Med have increased 27% with many articles in journals with the highest impact factors, reflecting substantial contributions to cancer research. Overall, grant funding has increased 80%. During the last 4 years, awarded NCI grant support has increased from $42M to $80M (90%). If present trends continue, NCI support will more than double by the time the CCSG is renewed. Research Programs have been reduced from 28 to 19 with one additional program in development. Criteria for program membership have been revised. The number of Shared Resources has increased from 13 to 20. Shared Resources include facilities for DNA analysis, nucleic acid extraction, sequence analysis, genomics, peptide synthesis, media preparation, research animal support, SCID mice, genetically engineered mice, small animal imaging, tissue procurement and banking, research histopathology, high resolution microscopy, flow cytometry and cellular imaging, pharmacology, human pedigree analysis, biostatistics, bioinformatics, clinical trials support, and protocol review and data monitoring. Funds are also requested for Development, Planning and Evaluation, Administration and for partial support of Senior Leadership and Program Leaders.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA016672-28
Application #
6676294
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ciolino, Henry P
Project Start
1998-09-04
Project End
2008-06-30
Budget Start
2003-08-15
Budget End
2004-06-30
Support Year
28
Fiscal Year
2003
Total Cost
$9,000,000
Indirect Cost
Name
University of Texas MD Anderson Cancer Center
Department
Type
Other Domestic Higher Education
DUNS #
800772139
City
Houston
State
TX
Country
United States
Zip Code
77030
Ji, Shuang; Ning, Jing; Qin, Jing et al. (2018) Conditional independence test by generalized Kendall's tau with generalized odds ratio. Stat Methods Med Res 27:3224-3235
McNeill, Lorna H; Reitzel, Lorraine R; Escoto, Kamisha H et al. (2018) Engaging Black Churches to Address Cancer Health Disparities: Project CHURCH. Front Public Health 6:191
Hosry, Jeff; Miranda, Roberto N; Samaniego, Felipe et al. (2018) Clinicopathologic characteristics and outcomes of transformed diffuse large B-cell lymphoma in hepatitis C virus-infected patients. Int J Cancer 142:940-948
Parkes, Amanda; Clifton, Katherine; Al-Awadhi, Aydah et al. (2018) Characterization of bone only metastasis patients with respect to tumor subtypes. NPJ Breast Cancer 4:2
Raber, Margaret; Huynh, To Nhu; Crawford, Karla et al. (2018) Development and Feasibility of a Community-Based, Culturally Flexible Colorectal Cancer Prevention Program. J Community Health 43:882-885
Wang, Xiaoxiao; Cao, Xin; Sun, Ruifang et al. (2018) Clinical Significance of PTEN Deletion, Mutation, and Loss of PTEN Expression in De Novo Diffuse Large B-Cell Lymphoma. Neoplasia 20:574-593
Koay, Eugene J; Owen, Dawn; Das, Prajnan (2018) Radiation-Induced Liver Disease and Modern Radiotherapy. Semin Radiat Oncol 28:321-331
Zhang, Yan; Coletta, Adriana M; Allen, Pamela K et al. (2018) Perirenal Adiposity is Associated With Lower Progression-Free Survival From Ovarian Cancer. Int J Gynecol Cancer 28:285-292
Rausch, Caitlin R; DiPippo, Adam J; Bose, Prithviraj et al. (2018) Breakthrough Fungal Infections in Patients With Leukemia Receiving Isavuconazole. Clin Infect Dis 67:1610-1613
Gu, Shenda; Ngamcherdtrakul, Worapol; Reda, Moataz et al. (2018) Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment. PLoS One 13:e0198141

Showing the most recent 10 out of 12418 publications